12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Canagliflozin regulatory update

Johnson & Johnson submitted an MAA to EMA for canagliflozin to treat Type II diabetes. In May, J&J submitted an NDA to FDA for the once-daily...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >